A pharmacist asks the technician to help document a suspected serious adverse drug reaction after a patient, Fenwick Adeyemi, was hospitalised following a new medicine. The technician wants to support voluntary reporting of the event to the national programme that monitors drug safety. Which programme is the correct destination for this report?
- AThe Prescription Drug Monitoring Programme that tracks controlled-substance dispensing
- BThe Drug Enforcement Administration registration database for controlled-substance handlers
- CThe FDA MedWatch programme for voluntary reporting of adverse events and product problems Correct
- DThe Recall Notification System that issues manufacturer product recalls to pharmacies
Why A is wrong: A prescription drug monitoring programme tracks controlled-substance prescriptions to detect misuse; it is not the channel for reporting adverse drug reactions, so this confuses two different surveillance systems.
Why B is wrong: The DEA registration system licenses entities to handle controlled substances; it has no role in collecting adverse drug reaction reports, so it is the wrong channel.
Why C is correct: MedWatch is the national voluntary programme for reporting serious adverse events and product problems, making it the correct destination for documenting this suspected reaction.
Why D is wrong: Recall notifications inform pharmacies of products being withdrawn; they communicate outward rather than collecting adverse-event reports, so this does not capture the suspected reaction.